Berenberg Bank set a €97.00 ($114.12) price objective on Sanofi SA (EPA:SAN) in a report published on Thursday morning. The firm currently has a neutral rating on the stock.

SAN has been the subject of a number of other research reports. Morgan Stanley set a €92.00 ($108.24) target price on shares of Sanofi SA and gave the stock a buy rating in a research report on Friday, October 6th. S&P Global set a €90.00 ($105.88) target price on shares of Sanofi SA and gave the stock a neutral rating in a research report on Monday, July 31st. Goldman Sachs Group, Inc. (The) set a €82.00 ($96.47) target price on shares of Sanofi SA and gave the stock a neutral rating in a research report on Tuesday, October 17th. J P Morgan Chase & Co set a €90.00 ($105.88) target price on shares of Sanofi SA and gave the stock a neutral rating in a research report on Tuesday, August 1st. Finally, BNP Paribas set a €85.00 ($100.00) price objective on shares of Sanofi SA and gave the company a neutral rating in a research report on Tuesday, September 12th. One research analyst has rated the stock with a sell rating, eleven have given a hold rating and five have issued a buy rating to the company’s stock. Sanofi SA has a consensus rating of Hold and a consensus price target of €87.24 ($102.63).

Sanofi SA (EPA:SAN) opened at €79.02 ($92.96) on Thursday. Sanofi SA has a 12-month low of €70.94 ($83.46) and a 12-month high of €92.97 ($109.38).

TRADEMARK VIOLATION WARNING: This news story was originally posted by Watch List News and is owned by of Watch List News. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international trademark and copyright law. The legal version of this news story can be accessed at https://www.watchlistnews.com/berenberg-bank-analysts-give-sanofi-sa-san-a-97-00-price-target/1681557.html.

Sanofi SA Company Profile

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.

Analyst Recommendations for Sanofi SA (EPA:SAN)

Receive News & Ratings for Sanofi SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi SA and related companies with Analyst Ratings Network's FREE daily email newsletter.